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The endocannabinoid system (ECS) has been placed in the anti-cancer spotlight in the
last decade. The immense data load published on its dual role in both tumorigenesis
and inhibition of tumor growth and metastatic spread has transformed the cannabinoid
receptors CB1 (CB1R) and CB2 (CB2R), and other members of the endocannabinoid-
like system, into attractive new targets for the treatment of various cancer subtypes.
Although the clinical use of cannabinoids has been extensively documented in the
palliative setting, clinical trials on their application as anti-cancer drugs are still
ongoing. As drug repurposing is significantly faster and more economical than de novo
introduction of a new drug into the clinic, there is hope that the existing pharmacokinetic
and safety data on the ECS ligands will contribute to their successful translation into
oncological healthcare. CB1R and CB2R are members of a large family of membrane
proteins called G protein-coupled receptors (GPCR). GPCRs can form homodimers,
heterodimers and higher order oligomers with other GPCRs or non-GPCRs. Currently,
several CB1R and CB2R-containing heteromers have been reported and, in cancer
cells, CB2R form heteromers with the G protein-coupled chemokine receptor CXCR4,
the G protein-coupled receptor 55 (GPR55) and the tyrosine kinase receptor (TKR)
human V-Erb-B2 Avian Erythroblastic Leukemia Viral Oncogene Homolog 2 (HER2).
These protein complexes possess unique pharmacological and signaling properties,
and their modulation might affect the antitumoral activity of the ECS. This review
will explore the potential of the endocannabinoid network in the anti-cancer setting
as well as the clinical and ethical pitfalls behind it, and will develop on the value of
cannabinoid receptor heteromers as potential new targets for anti-cancer therapies and
as prognostic biomarkers.
Keywords: endocannabinoids, G protein-coupled receptor, cannabinoid CB1 receptor, cannabinoid CB2 receptor,
ethical issues, marijuana legalization, receptor heteromer
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INTRODUCTION
The term endocannabinoid system (ECS) refers to a complex
network of cannabinoid receptors, endocannabinoid ligands, the
enzymatic machinery that drives their biosynthesis, degradation,
transport and all cells and neurological pathways that involve
endocannabinoid signaling (Figure 1). It is implicated in the
control of the most vital processes thus creating homeostasis
within the organism, which explains its ambiguous role in
tumorigenesis and suppression of tumors.
The ECS components were gradually described in the late
1980s and early 1990s during the search for the pharmacological
targets of 19-tetrahydrocannabinol (THC) isolated from the
plant Cannabis sativa (marijuana) (Devane et al., 1988;
Matsuda et al., 1990). The discovery was a classical success story
that went much beyond the intended purpose of providing
mechanistic proof for the psychotropic effects of cannabinoids.
As cannabinoid consumption was alarmingly rising especially
in more developed countries, a lot of funding was invested
in projects trying to decipher the exact mode of its action
in order to strengthen the publics “no” vote for marijuana
legalization (Thomas, 2001). However, the fact that marijuana
was also invaluable in easing the symptoms of many other
conditions (nausea, pain, motor dysfunctions, cardiovascular,
gastrointestinal and reproductive problems etc.) could not be
ignored for long. Considering the range of its benefits, it was
obvious that all these effects must be explained through the action
of various active components of C. sativa not on a single target in
the brain but rather on a more complex entity.
The ECS has been placed in the anti-cancer spotlight in
the last decade. The immense data load published on its dual
role in both tumorigenesis and inhibition of tumor growth and
metastatic spread has made it into attractive new target for
the treatment of various cancer subtypes. Although the search
FIGURE 1 | A schematic representation of the main components of the
endocannabinoid system (ECS). CBR – cannabinoid receptor, GPR – G
protein-coupled receptor, PPAR – peroxisome-proliferator-activated receptors,
FAAH – Fatty acid amide hydrolase, MAGL – Monoacylglycerol lipase, PLC –
Phospholipase C, DAGL – Diacylglycerol lipase, ABHDx – Alpha beta
hydrolase domain proteins, HSP – heat shock proteins, FLAT – FAAH-like
anandamide transporter.
for cancer biomarkers usually favors single targets that enable
the exploitation of a biochemical or genetic weakness, marking
the vast ECS as a pharmacologically targetable entity brings as
many advantages as complications. This review will explore the
potential of the ECS in the anti-cancer setting as well as the
clinical and ethical pitfalls behind it, and will develop on the value
of cannabinoid receptor heteromers as potential new targets for
anti-cancer therapies and as prognostic biomarkers.
THE DISCOVERY OF THE CANNABINOID
RECEPTORS
The first components of the ECS that were discovered were THC
target sites in the brain. These receptors were named cannabinoid
receptors (CBR), but it was still unknown that they represent one
of the most abundant neurotransmitter receptors in the whole
organism. The first discovered and cloned receptor was named
CB1R (Matsuda et al., 1990) and it was concluded that THC
exerts a presynaptic inhibition of normal endogenous signaling
of this receptor leading to the known psychotropic effects in the
central nervous system (CNS) (Roth, 1978). The second identified
ECS receptor was found in non-CNS sites, mostly on cells of the
immune system, and was named CB2R (Munro et al., 1993). This
discovery was a promising start for the search of the other factors
involved in the non-psychotropic effects of cannabinoids, as it
was found that ligands of CB2R are responsible for their observed
immunomodulatory effects (Acharya et al., 2017). Both receptors
are expressed in the periphery as well, regulating vital processes in
the gastrointestinum, lungs, skin, kidneys, reproductive system,
liver, lymph nodes, bones, etc.
The human central cannabinoid receptor gene 1 (CNR1) is
located on chromosome 6 (6q15, HGNC ID: 2159) (HUGO), and
it encodes three isoforms of a 60 kDa CB1R protein (UniProtKB –
P21554) (UniProtKB). It is expressed in CNS areas that control
motor behavior, memory and learning, emotions, sensory and
endocrine functions, as well as in peripheral nerves and in other
extra-neural locations (Atwood and Mackie, 2010). CB1R are
mostly located presynaptically and mainly coupled to inhibitory
Gi/o proteins, which among other effects inhibit adenylate cyclase
and lead to a decrease of intracellular cAMP levels. The activation
of CB1R at glutaminergic and GABAergic neuron membranes
by endocannabinoids inhibits the release of excitatory and
inhibitory neurotransmitters (glutamate, GABA, acetylcholine,
dopamine, D-aspartate, noradrenaline, etc.). Thus, CB1R and its
ligands contribute to the plasticity of neurotransmission, and are
attractive pharmacological targets.
The human central cannabinoid receptor gene 2 (CNR2)
is located on chromosome 1 (1p36.11, HGNC ID: 2160)
(HUGOb) and it encodes multiple isoforms of a 40 kDa CB2R
protein (UniProtKB – P34972) (UniProtKBb). CB2R are also
mostly located presynaptically and mainly coupled to inhibitory
Gi/o proteins, so 2-AG and other CB2R ligands have various
roles in the regulation of immune responses and peripheral
neurotransmission. The CB2R was firstly detected in the immune
system (Pertwee et al., 2010), but over time its expression was also
detected in other cell types. The presence of CB2R in microglial
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cells during neuroinflammation has been well documented, but
it has also been detected in astrocytes and some subpopulations
of neurons (Munro et al., 1993; Fernandez-Ruiz et al., 2007;
Atwood and Mackie, 2010). As agonists that bind to CB2R
usually lack the psychotropic effects seen upon CB1R agonist-
based treatments, the selective targeting of CB2R in the CNS and
the periphery might be a perspective approach for the treatment
of various neurological disorders.
CB1R and CB2R Are GPCRs
Cannabinoid receptors belong to an extensive family of class A
rhodopsin-like G-protein coupled receptors (GPCR), important
for transducing signals from the extracellular space to a variety
of intracellular signaling molecules (Matsuda et al., 1990;
Munro et al., 1993; Pertwee et al., 2010). It is not by chance
that the ECS receptors are GPCRs, as the chemical variety
of ligands that bind and activate them is extraordinary.
GPCRs form the most extensive human membrane protein
family, with about 826 members in the human proteome
(Cvicek et al., 2016; Shimada et al., 2018). According to their
sequence homology, phylogenetic analyses and after the Human
Genome Project was completed, Fredriksson et al. (2003)
classified GPCRs into five families: rhodopsin (class A, 701
members), secretin (class B, 15 members), glutamate (class
C, 15 members), adhesion (24 members) and frizzled/taste
(class F, 24 members). Currently, IUPHAR identifies six
main classes: the A–F classes, containing human receptors,
and classes D and E, including GPCRs of other species
with no human orthologs (Sharman and Mpamhanga, 2011).
GPCRs are main players in cell communication and transduce
sensory signals of external origin, such as odorants and
taste molecules, light and endogenous stimuli such as
hormones, neuropeptides, neurotransmitters, purine ligands,
chemokines, calcium ions, etc. Recently, conformational
modifications that mediate GPCR activation have been
described, as well as the structural conformation of the
receptors necessary to interact with the three classes of proteins
that preferentially bind to activated GPCRs: heterotrimeric G
proteins, GPCR kinases and β-arrestins (Vilardaga et al., 2010;
González et al., 2014; Wells, 2014; Gurevich and Gurevich, 2017;
Wang et al., 2017).
G protein-coupled receptors, also known as heptahelical or
seven-transmembrane (TM) receptors, are cell surface proteins
with a common topology comprised by an extracellular (EC)
N-terminus and a cytoplasmic C-terminus with an amphiphilic
α-helix (H8) alongside the cell membrane. They have 7 TM
α-helices connected by 3 intracellular (ICL) and 3 extracellular
loops (ECL) and a disulphide bridge between ECL2 and TM3
(González et al., 2014; Baltoumas et al., 2016). The 7TM bundle
can be divided into EC and IC regions. The N-terminus varies
in length from relatively short and unstructured (such as many
class A members) to long and with many globular domains
and conserved secondary structure (such as class C members).
The IC module includes the ICLs, a short helix 8 and an IC
C-terminus (Katritch et al., 2012; Di Pizio et al., 2016); it is more
conserved among GPCRs, in contrast to the EC region, and is
responsible for interaction with intracellular proteins implicated
in feedback modulation and signal transduction of receptor
function (Moreira, 2014; Di Pizio et al., 2016).
The orthosteric binding site of a receptor is the canonical site
where the natural ligand binds. Its location can vary markedly
between different subclasses of GPCRs and can be found in
different positions within the TM bundle or in an extracellular
pocket. Ligand binding to this orthorteric site produces
conformational changes in the receptor’s cytosolic region
facilitating binding and the activation of downstream signaling
effectors such as β-arrestins and G proteins (Staus et al., 2016).
The orthosteric binding pocket can bind both native or synthetic
ligands termed orthosteric ligands. Other ligands targeting
GPCRs are currently classified as allosteric, bitopic/dualsteric or
bivalent ligands (Feng et al., 2015).
However, elucidation of the GPCRs crystal structures, along
with molecular modeling and functional studies, provides insight
into the binding mode of natural or synthetic ligands and
open new opportunities for the design of next-generation
GPCR drugs. In the last years, the number of receptors that
have been crystallized has greatly increased and more than
250 structures of 50 different GPCRs have been solved in
complex with agonists, antagonists, antibodies, peptides or G
proteins (Venkatakrishnan et al., 2013; Shonberg et al., 2015;
Shimada et al., 2018). From the elucidated crystal structures of
class A GPCRs, it is deduced that ligand binding occurs in a
main pocket found between the EC segments of TMs 3, 5, 6,
and 7 or in a minor cavity found between the EC segments of
TMs 1, 2, 3, and 7 (Gonzalez et al., 2014). Although GPCRs
present these common cavities, different ligands can penetrate to
various depths within the TM bundle, so that this structural core
binds ligands in the EC module and transfers the information to
the IC module. It is the most conserved structural component
of GPCRs, showing characteristic hydrophobic patterns and
functional motifs (Katritch et al., 2012; Di Pizio et al., 2016).
Structural studies with class A receptors, have revealed the
existence of a conformational change upon receptor activation
which include a breaking of “the ionic lock formed between TM6
and the D(E)RY motif in TM3, and movements of the TM5
and TM6 cytoplasmic segments and the ICL3,” with some minor
rearrangements in the TM3 helix (Baltoumas et al., 2016).
In the case of cannabinoid receptors, unbiased molecular
dynamics has demonstrated that a ligand can penetrate the
binding pocket of a class A GPCR via the lipid bilayer.
Effectively, Hurst et al. (2010), using microsecond time scale
all-atom molecular dynamics (MD) simulations, showed that
the endogenous cannabinoid sn-2-arachidonoylglycerol (2-AG)
accesses to the CB2R passing throughout the lipid bilayer. Their
results suggest that 2-AG penetrates the CB2R binding pocket
by passing between TM6 and TM7 (Hurst et al., 2010). In 2016,
Shao et al. (2016) crystallized the human CB1R thermostabilized
by the inverse agonist taranabant, and solved its atomic structure
at 2.6-Å resolution. They confirmed a gap between TM1 and
TM7 in the EC leaflet that could contribute to a membrane-
embedded access channel for lipophilic agonists of CBRs. In
order to facilitate the entry of ligands, a subsequent dilatation of
the conserved residues (Ile1191.35, Phe3817.37, and Met3847.40)
would be required. At the same time, Hua et al. (2016) crystallized
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CB1R bound to AM6538, an antagonist with a nitrate group
substituted on the chlorophenyl moiety of rimonabant. The
two structures are in good agreement, but the taranabant-
bound and AM6538-bound CB1R structures represent an
inactive conformation with respect to G-protein binding. Later,
Hua et al. (2017) reported two crystal structures of human CB1R
in complex with agonists: a hexahydrocannabinol (AM841) and
a tetrahydrocannabinol (AM11542), with a resolution of 2.95
and 2.80 Å, respectively. These CB1R-agonist complexes showed
relevant conformational changes compared with the CB1R-
antagonist structures, that is, a 53% reduction in the volume of
the ligand-binding pocket and an increment in the surface of the
G-protein binding region (Hua et al., 2017).
GPCRs Form Oligomeric Protein
Complexes
Since the early 80s the concept on intramembrane receptor-
receptor interactions was introduced and the first experimental
evidence was reported for their existence in crude membrane
preparations from different CNS areas (Agnati et al., 1980; Fuxe
et al., 1981; Fuxe and Agnati, 1985). Since then, many evidence
show that GPCRs do not act exclusively as monomeric proteins
(Agnati et al., 2005; Fuxe et al., 2007). Kniazeff et al. (2011)
reviewed that dimer formation is a prerequisite for canonical
receptor function in class C GPCRs, and Xue et al. (2015)
demonstrated that the mGluR2 dimer interface switches from
TM4-TM5 in the inactive state to TM6-TM6 interactions
in the active conformation, revealing a key step in class
C GPCR activation. In the large subfamily A of GPCRs,
although several receptors are able to operate as monomers
(Chabre and le Maire, 2005; Ernst et al., 2007; Hanson et al., 2007;
Whorton et al., 2007, 2008; Kuszak et al., 2009; Arcemisbéhère
et al., 2010; Bayburt et al., 2011), experimental data have
shown that most receptors could be expressed as a mixture of
monomers and homodimers/oligomers (Teichmann et al., 2014;
Vischer et al., 2015; Franco et al., 2016; Nemoto et al., 2016),
and that oligomerization is necessary for the maturation of
the receptor, its inclusion in the membrane and its function
(Angers et al., 2000, 2002; Fotiadis et al., 2003; Herrick-Davis
et al., 2006; Lopez-Gimenez et al., 2007; Han et al., 2009; Wade
et al., 2011; Ng et al., 2013; Hurevich et al., 2014; Liste et al.,
2015; Gahbauer and Böckmann, 2016; Lao et al., 2017; Jin
et al., 2018). Fung et al. (2009) reported receptor oligomers,
mostly with tetrameric structure, of β2-adrenergic receptors after
reconstitution into phospholipid vesicles. Albizu et al. (2010)
demonstrated the in vivo existence of native oxytocin receptor
dimers and Herrick-Davis et al. (2012, 2013, 2015) provided
strong experimental evidence that adrenergic, muscarinic,
dopamine, and serotonin 5-HT2C receptors form homodimers
endogenously expressed in their cellular environment. Using
dual color photoactivation localization microscopy with
photoactivatable dyes, Jonas et al. (2015) reported that the
luteinizing hormone receptor (LHR) is organized in a mixture
of monomers, dimers and lower order oligomers at the plasma
membrane with distinct spatial geometries. Likewise, M1
muscarinic receptor, D2 dopamine receptor, β1-adrenergic
receptor and chemokine receptor (CXCR4) can exist in a
dynamic equilibrium between monomers/dimers/oligomers,
that can be regulated by selective agonists, antagonists or
bivalent ligands (Calebiro et al., 2013; Pediani et al., 2016;
Tabor et al., 2016). Cai et al. (2017) demonstrated monomer-to-
dimer interconversion of the class A apelin receptor (APJ) on
the cell membrane, with APJ dimers possessing new functional
characteristics after agonist activation, such as distinct G-protein
binding profile and cell responses. Recently, Parmar et al. (2017),
using BRET, bimolecular fluorescence complementation (BiFC)
and fluorescence correlation spectroscopy (FCS) indicated that
the β2-adenergic receptors are predominantly homodimers, and
Jastrzebska et al. (2017) demonstrated that the human red cone
opsin forms a stable dimer in the live cell membrane with the
existence of three essential amino acids, I230, A233 and M236
that are required for dimerization.
Furthermore, a multitude of other class A GPCRs have
been also found to form homomers, specially in the last
decade, such as cannabinoid CB1, adenosine A1, A2A
and A3, adrenergic α1B, dopamine D1 and D3, serotonin
5HT1A, 5HT2A, and 5HT7, δ, κ and µ opioid, angiotensin
AT1, muscarinic M2 and M3, melatonin MT2, and niacin
receptors (Cvejic and Devi, 1997; Jordan and Devi, 1999;
He et al., 2002; Ayoub et al., 2004; Goin and Nathanson, 2006;
Łukasiewicz et al., 2007; Mandrika et al., 2010; Teitler et al.,
2010; Gracia et al., 2011, 2013; May et al., 2011; Pou et al., 2012;
Szalai et al., 2012; Herrick-Davis et al., 2013; Guitart et al., 2014;
Bonaventura et al., 2015; Bagher et al., 2017).
G protein-coupled receptors are not only present as
monomers and homomers but also form heteromers with other
GPCRs (Smith and Milligan, 2010; Ferré et al., 2014; Gomes
et al., 2016a; Farran, 2017; Gaitonde and González-Maeso, 2017;
Guidolin et al., 2018). GPCR heteromers with two or
more receptor protomers are macromolecular complexes
with biochemical properties clearly different from those
of its individual components (Ferré et al., 2009, 2014;
Gomes et al., 2016a). Three consensus criteria have been
published by the International Union of Basic and
Clinical Pharmacology to classify a true GPCR heteromers
(Kenakin et al., 2010). The first criterion indicates that
the heteromer components must co-localize to the same
subcellular compartment and physically interact in native tissues
(Albizu et al., 2010; Hounsou et al., 2015; Gomes et al., 2016a).
The second consensus criteria requires that the heteromers
must exhibit specific properties, that differ from those associated
with the individual protomers, such as trafficking, ligand
binding and signaling (biochemical fingerprint) (Jordan and
Devi, 1999; Hillion et al., 2002; Terrillon et al., 2004; Sohy
et al., 2007; Gomes et al., 2011, 2016a; González et al., 2012;
Kern et al., 2012; Bellot et al., 2015; Jonas et al., 2018). Finally,
criterion 3 postulates that heteromer disruption brings about
a loss of interaction and, therefore, to a loss of the typical
biochemical fingerprint of the heteromer (Baba et al., 2013;
Fujita et al., 2015; Gomes et al., 2016a). Respect to the second
criterion, according to Cortés et al. (2016), there are three
major allosteric modulations in GPCR heteromers that imply
alterations of the affinity and/or efficacy of a ligand by a protomer
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within the heteromer due to binding of an allosteric modulator
in any site of the heteromer, or to binding of an orthosteric
ligand in the other protomer or to the simple presence of the
other protomer within the heteromer (Kenakin and Miller,
2010; Wootten et al., 2013; Ferré et al., 2014; Ferré, 2015;
Casadó-Anguera et al., 2016).
Although many GPCR heteromers have been identified
using heterologous cell lines, only very few fit all three
criteria. This is mainly due to the difficulties to study these
structures in native tissues because of the lack of sensitive
and selective enough tools, able to detect in vivo evidence of
these endogenous heteromers and to demonstrate that they
are close enough to interact (Gomes et al., 2016b). Therefore,
the accomplishment of at least two out of three criteria is
required for the acceptance of a GPCR heteromer (Jonas
and Hanyaloglu, 2017). The main strategies to target GPCR
heteromers are the generation of selective compounds, which
exhibit higher efficacy in tissues from wild type animals or
in cells expressing both receptors than in knock-out animals
tissues or in cell only expressing the individual receptors
(Akgün et al., 2013; Gomes et al., 2013a; Molero et al., 2015;
Nimczick and Decker, 2015; Peterson et al., 2017). Likewise,
the use of membrane-permeable peptides that target the
dimerization interface or heteromer-selective antibodies that can
recognize an epitope in the heteromer but not in the individual
protomers, have been most useful to detect GPCRs heteromers
in vivo (Gupta et al., 2010; He et al., 2011; Viñals et al., 2015;
Gomes et al., 2016a; Moreno et al., 2017; Jacobs et al., 2018).
Finally, it is important to note the existence of single-molecule
techniques, which are ideal for understanding the conformational
complexity and dynamic signaling of GPCRs (Tian et al., 2017).
Their application in living cells can provide the tools to directly
visualize individual receptors in homomers and heteromers and
how GPCRs can move about and interact in the presence
of diverse ligands (Jonas et al., 2016; Scarselli et al., 2016;
Calebiro and Sungkaworn, 2018).
A basic heterotetrameric structure formed by two
homomers of a Gs-coupled and a Gi-coupled receptor has
been reported for the dopamine D1-D3 receptor heteromer
(Guitart et al., 2014), the adenosine A1-A2A receptor heteromer
(Navarro et al., 2016), the adenosine A2A-dopamine D2
receptor heteromer (Bonaventura et al., 2015; Casadó-Anguera
et al., 2016; Borroto-Escuela et al., 2018; Navarro et al., 2018),
and the adenosine A1-dopamine D1 receptor heteromer
(Rivera-Oliver et al., 2018).
Cannabinoid Receptors Heteromers
Cannabinoid receptors have been described for a long time as
constituents of particular GPCR receptor heteromers. CB1Rs
have been demonstrated in the past to interact with other
GPCRs, such as adenosine A2A receptors (Carriba et al., 2007;
Moreno et al., 2018), dopamine D2 receptors (producing a
change in the coupling from Gi to Gs) (Glass and Felder, 1997;
Kearn et al., 2005; Marcellino et al., 2008), D2 and adenosine
A2A receptors at the same time (generating a negative
modulation of the function of D2 receptor by A2A and
CB1 agonists) (Carriba et al., 2008; Navarro et al., 2010;
Bonaventura et al., 2014), opioid µ and δ receptors (producing
a negative cross-talk between receptors) (Rios et al., 2006),
orexin OX1 receptors (producing a positive cross-talk and cross-
antagonism by orexin) (Hilairet et al., 2003; Ellis et al., 2006),
angiotensin AT1 receptors (with an increase of AT1 receptor
signaling) (Rozenfeld et al., 2011), CB2R (negative cross-talk
and bidirectional cross-antagonism in neuronal cells in culture
and in vivo is produced by the coactivation of both receptors)
(Callén et al., 2012), adrenergic β2 receptor (adrenergic agonists
inducing CB1R internalization) (Hudson et al., 2010), and
5HT2A serotonin receptor (Viñals et al., 2015). Also, CB1R can
form heteromers with the cannabinoid-related orphan receptor
GPR55 in HEK-293 cells (Kargl et al., 2012; Martínez-Pinilla
et al., 2014). Contrary to CB1R, not much is known about the
existence and functional importance of heteromers concerning
CB2R, however, there is evidence of its interaction with GPR55
in transfected cells (Balenga et al., 2014) and with CXCR4 (Coke
et al., 2016; Scarlett et al., 2018).
THE DISCOVERY OF
ENDOCANNABINOIDS
The first discovered and most abundant endocannabinoids
were anandamide (N-arachidonoyl ethanolamide, AEA)
(Devane et al., 1992) and 2-arachydonoyl glycerol (2-AG)
(Mechoulam et al., 1995), derivatives of ω-6 arachidonic acid
(ARA), an essential polyunsaturated fatty acid (PUFA). Beside
AEA and 2-AG, other unsaturated lipid-based molecules have
been classified as endocannabinoids due to their function
and comparably high levels (N-arachidonoyl dopamine,
N-oleoyldopamine, homo linoleoyl ethanolamide (HEA),
docosa tetraenyl ethanolamide, virodhamine, noladin ether,
palmitoyl ethanolamide, oleoylethanolamide, oleamide,
eicosapentaenoylethanolamide, sphingosine, hemopressin,
etc.) (Pertwee, 2015; Nikan et al., 2016). The significance of these
small molecules is highlighted by the fact that their signaling
pathways exist even in very primitive organisms where they
regulate a range of vital processes (De Petrocellis et al., 1999).
They are produced and are active inside the body upon demand,
and they exert a regulatory role of adaptive cellular responses to
various endogenous and environmental stimuli that endanger
internal homeostasis.
Endocannabinoid signaling is not a classical example of
neurotransmission, as their effects are mostly restricted to local
sites of their biosynthesis and release. Their biosynthesis precedes
the stimuli, and they are stored in synaptic vesicles until
needed. Once they have exerted their effect on the receptors
of postsynaptic neurons, they are transported back to the
presynaptic neuron terminating the short-lived response to a
stimulus (Lu and Mackie, 2016). As exogenous cannabinoids are
usually supplied in excess they can take over the endocannabinoid
signaling for longer time periods, leading to a range of
physiological effects. Beside CB1R and CB2R, other receptors
have been found to be the targets of endocannabinoids and
exocannabinoids in the CNS and in tumor tissues, including the
transient receptor potential channels, ligand and voltage-gated
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ion channels and other orphan G protein-coupled receptors as
GPR55, GPR18 and GPR119 (Soderstrom et al., 2017). Receptor-
independent regulatory effects of endocannabinoids have also
been documented, contributing to the plasticity of the ECS
(Lu and Mackie, 2016).
Non-ARA Based Endocannabinoids
Beside the most common endocannabinoid derivatives of ARA,
other classes of lipid-based molecules important for the ECS
have been detected in high enough levels to be classified as
endocannabinoids (McDougle et al., 2017). ω-3 PUFAs, such as
docosahexaenoic acid (DHA) and eicosapentaenoic acid (EPA),
convert to a range of biologically active molecules important
for proper functioning of essential biochemical processes in the
body. These epoxyeicosatetraenoic acid-ethanolamides (EEQ-
EA) and epoxydocosapentaenoic acid-ethanolamides (EDP-
EA) are formed through the action of cytochrome P450
epoxygenase, and have been found to preferentially stimulate
CB2Rs and induce anti-inflammatory and antiangiogenic effects
(McDougle et al., 2017). The complexity of the ECS can also
be seen in the constant interplay of ω-3 and ω-6 PUFA
based endocannabinoids, as well as in the sharing of the
biosynthetic/degradative and regulatory levels by various classes
of endocannabinoids, which influences the final outcome of a
specific stimuli (Dyall, 2017).
Binding of Endo- and Exocannabinoids
to Cannabinoid Receptors
Exogenous cannabinoids (plant-derived and synthetic)
bind to CBRs as their binding pocket is flexible and can
interact with ligands that are not the exact size and shape
match to their designated endocannabinoids (Sim-Selley,
2003). As a consequence, all the processes regulated by
endocannabinoids are susceptible to the interference of
exogenous cannabinoids (allosteric, bitopic/dualsteric or
bivalent ligands), and their effects have been extensively
documented in various settings (pregnancy/infertility, motor
functions, CNS development, etc). THC binds to CB1R
instead of anandamide on neurons, but also to CB2R on
immune cells which changes the endogenous response to
infection and also reduces inflammation. 2-AG also has a
mimetic plant cannabinoid called cannabidiol (CBD) which
exerts its mostly health promoting effects by competing with
2-AG for its binding places on CB2R and other receptors
(Iﬄand and Grotenhermen, 2017). These effects are even more
pronounced in conditions where ECS signaling is impaired
(Clinical Endocannabinoid Deficiency) due to external factors
as stress, diet, medicaments or internal ones involving a
dysbalance between the biosynthesis, breakdown and transport
of endocannabinoids (Russo, 2016). Thus, the observed
clinical benefits of exogenous cannabinoids have a strong
biochemical rational.
However, the effects of exocannabinoids cannot be
considered as a simple receptor-takeover as they do not act
as mere substitutes for endocannabinoids. Depending on their
concentration, abundance of receptors and the levels and activity
of endogenous ligands and enzymes, agonism, antagonism
and inverse agonism of cannabinoid and non-cannabinoid
receptors can occur (Pertwee, 2015; Lu and Mackie, 2016).
In vitro evidence shows that around 13 endogenous compounds
have been detected so far that can bind to these receptors
orthosterically or allosterically (Pertwee, 2015), while AEA and
2-AG are the main orthosteric ligands.
Apart from orthosteric ligands, several allosteric modulators
for CBRs have been discovered. While cannabinoids interact
with the orthosteric receptor site, these novel CBR ligands
bind the receptor at sites topographically distinct from the
orthosteric binding site, modifying the receptor conformation
and leading its novel properties and modes of action
(Conn et al., 2009; Fay and Farrens, 2013; Shore et al., 2014;
Stornaiuolo et al., 2015; Foster and Conn, 2017). The allosteric
cannabinoid ligands modulate the CBR activity by altering
the affinity and/or the efficacy of an orthosteric ligand in
either a positive (positive allosteric modulator, PAM) or
negative (negative allosteric modulator, NAM) manner.
In the last decade, many allosteric modulators for CB1R
have been reported (Nguyen et al., 2017; Scott and Kendall,
2017; Dopart et al., 2018). Examples of CB1R NAM are
ORG27569, ORG27759, and ORG29647 (Price et al., 2005;
Ahn et al., 2013), PSNCBAM-1 (Horswill et al., 2007), pepcans
(Bauer et al., 2012), pregnenolone (Vallée et al., 2014) and
CBD (Laprairie et al., 2015). CB1R PAM are RTI-371 (Navarro
et al., 2009), lipoxin A4 (Pamplona et al., 2012), GAT211
and its enantiomer GAT229 (Laprairie et al., 2017b), and
ZCZ011 (Ignatowska-Jankowska et al., 2015). Recently, some
modulators of CB2R have also been described; Martínez-
Pinilla et al. (2017) reported that CBD could also act as a
NAM of CB2R because it is able to negatively modulate the
binding and functional effect of CB2R agonists; Petrucci
et al. (2017) reported that pepcan-12 is a potent CB2R
PAM and, very recently, Pandey et al. (2019) described
DHGA and TBC as CB2R NAMs, decreasing the binding
of the orthosteric agonist CP55,940. The therapeutic
usefulness of these cannabinoid allosteric modulators
is emerging, and they offer an exciting potential for
mechanistic analyses and for the development of therapeutics
(Scott and Kendall, 2017).
THE DISCOVERY OF THE
ENDOCANNABINOID ENZYMATIC AND
TRANSPORT SYSTEMS
The last ECS component that was described in more detail was
the enzymatic machinery behind the biosynthesis, degradation
and transport of endocannabinoids. Endocannabinoids are
lipid neuromodulators produced on-demand making the
ECS a fast acting and adaptive entity. Anandamide and 2-
arachydonoyl glycerol have very similar chemical structures
(Figure 1) but the pathways involved in their biosynthesis
and degradation are completely different, highlighting their
distinct physiological roles. They are both derivatives of
arachidonic acid, an essential PUFA, but while anandamide
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is synthesized mostly from N-arachidonoyl phosphatidyl
ethanol by various pathways, 2-AG is produced mainly
from phosphatidyl inositol bis-phosphate in a calcium-
dependent manner involving phospholipase C (PLC) and
diacylglycerol lipase (DAGL) (Lu and Mackie, 2016). Also,
fatty acid amide hydrolase (FAAH) primarily hydrolyzes AEA
in the endoplasmic reticulum, and monoacylglycerol lipase
(MAGL) is the primary hydrolytic degrader of 2-AG, with
FAAH and some serine hydrolases (ABHD6 and ABHD12)
as proposed secondary degraders (Savinainen et al., 2012).
Levels of endogenous cannabinoids depend also on the activity
of their uptake and effective transport in the cell, as they
are hydrophobic and cannot diffuse through the cytosol and
cell membrane easily. Many carriers and molecules have
been implicated in this process depending on the cell type,
as heat shock proteins, serum albumin and other fatty-acid
binding proteins as FAAH-like anandamide transporter (FLAT),
cholesterol, ceramides (Nicolussi and Gertsch, 2015; Di Scala
et al., 2018). Once AEA reaches the target receptors on cells,
and exerts its effects, it is recycled back to the cytoplasm
and is subjected to enzymatic hydrolysis. Some exogenous
cannabinoids, as CBD for example, can interfere with AEA
FAAH-mediated breakdown, raising the levels of available
AEA, thus indirectly inducing various non-psychoactive effects
(Bisogno et al., 2001).
ECS COMPONENTS IN ANTI-CANCER
THERAPY
The mechanisms involved in the regulation of ECS as well as
the processes that it regulates include practically every pathway
important in cancer biology. So it is not a matter of chance
that ECS components can exert antiproliferative, proapoptotic,
antiangiogenic, anti-metastatic and anti-inflammatory effects
depending on tumor type and specific setting. Cannabinoid
receptors and endocannabinoids are generally up-regulated in
tumors (Sanchez et al., 2001; Guzmán, 2003; Caffarel et al.,
2006; Malfitano et al., 2011), and their expression levels can
be linked to tumor aggressiveness (Nomura et al., 2010; Thors
et al., 2010; Malfitano et al., 2011). These data imply that an
over-activation of ECS might be a pro-tumorigenic factor
(Malfitano et al., 2011), but considering the complexity of this
system, the effects it induces depend on many factors. The various
implications of the ECS in different cancer types have been
reviewed in Table 1.
Cannabinoid Receptors in Cancer
There are in vivo reports showing that genetic ablation
of CB1R and CB2R leads lower the skin-cancer inducing
potential of UV light (Zheng et al., 2008), and that over-
expression of CB2R contributes to a higher risk of leukemia
upon leukemia virus infection (Joosten et al., 2002). On the
contrary, there are reports implying that pharmacological
activation of CBRs leads to a reduction of tumor growth
(Guzmán, 2003; Sarfaraz et al., 2008), suggesting that ECS
signaling might induce tumor-suppressive effects. This
opinion is reinforced by in vivo reports that the deletion of
CB1R accelerates tumor growth (Wang et al., 2008), that the
presence of higher endocannabinoid levels lead to a reduction of
precancerous lesions (Izzo et al., 2008), and that lower expression
of MAGL decreases tumor growth (Nomura et al., 2010;
Velasco et al., 2015).
The expression of CB1R and CB2R in cancer cells and
the cells originating from the same tissue often does not
correlate well (Guzmán et al., 2006; Fernandez-Ruiz et al., 2007;
Sarfaraz et al., 2008; Velasco et al., 2012). Different types of
tumor cells can over-express CB1R and/or CB2R and are
as such very attractive for various anti-cancer approaches
(Pagano and Borrelli, 2017). On the other side, there are
reports that the loss of expression of CB1R and/or CB2R can
lead to acceleration of tumor growth (Wang et al., 2008).
Thus, their significance as prognostic and/or predictive
factors for targeted therapies must be explored in more
detail for each cancer subtype, especially when biased
agonism is taken into account (Laprairie et al., 2017a).
Exploring the ECS non-receptor mechanisms is also a
promising approach, as receptor expression does not have a
straight forward correlation with tumorigenicity (Soderstrom
et al., 2017). There are reports that the activation of CBRs
leads to apoptosis of tumor cells and inhibition of their
dissemination through the regulation of RAS/MAPK and PI3K–
AKT pathways (Pagano and Borrelli, 2017), TNFα-induced
ceramide synthesis (Cianchi et al., 2008), endoplasmic
reticulum stress-related genes (Carracedo et al., 2006a),
COX-2-dependent cell death (Patsos et al., 2010), inhibition
TABLE 1 | The implication of the endocannabinoid system in different cancer types.
ECS component Type of effect Cancer type References
CB1R Gene/Protein overexpression Glioma, astrocytoma Galve-Roperh et al., 2000; Cudaback et al., 2010
CB2R Gene/Protein overexpression Glioma, melanoma, astrocytoma,
breast, hepatic, pancreatic cancer
Sanchez et al., 2001; Lorente et al., 2011; Velasco
et al., 2012
CB2R-CXCR4 Heteromerization Breast, prostate cancer Coke et al., 2016; Scarlett et al., 2018
CB2R-GPR55 Heteromerization Breast cancer Moreno et al., 2014
HER2-CB2R Heteromerization Breast cancer Pérez-Gómez et al., 2015; Blasco-Benito et al., 2019
Anandamide Upregulation Colon cancer Patsos et al., 2010
FAAH Gene/Protein overexpression Prostate cancer Thors et al., 2010
MAGL Gene/Protein overexpression Breast, ovarian, melanoma, colorectal Granchi et al., 2017; Pagano et al., 2017
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of neo-angiogenesis (Pisanti et al., 2007), and many other
proposed mechanisms.
Heteromers as Potential Targets
Because GPCRs allosterically facilitate the transfer of information
across the cytoplasmic membrane responding to extracellular
signals, they acquire an essential role in the mediation of signal
transduction. In turn, this renders GPCRs therapeutic targets
in a wide number of diseases, either due to their capacity to
regulate a set of signaling cascades implicated in a specific
disease or due to their direct involvement in the pathophysiology
of this disease (Lefkowitz, 2004; Cvicek et al., 2016). Over
90% of described GPCRs are expressed in the CNS and are
crucial for the appropriate functioning of many neurological
actions (Vassilatis et al., 2003). Thus, it is not surprising that,
in clinical medicine, they are the most important class of
membrane proteins. Currently, more than 30% of all US Food
and Drug Administration (FDA) approved drugs target GPCRs
(Shimada et al., 2018), and these drugs are utilized in a wide range
of therapeutic areas, including cancer, inflammation and diseases
of the CNS, cardiovascular, respiratory and gastrointestinal
dysfunctions, diabetes, obesity, and pain (Feng et al., 2015).
Hauser et al. (2017) pointed out that more than 300 agents were in
clinical trials in that moment, of which around 60 targeted novel
GPCRs for which no drug had yet been approved.
Nevertheless, despite “the proven success of GPCRs as
drug targets, clinically useful ligands do not exist for the
majority of GPCRs” (Ferré et al., 2014). This is probably
because the true target of the GPCRs are not the individual
(monomeric) receptors but heteromeric complexes with other
GPCRs, other receptors or other membrane, cytosolic or
extracellular proteins, in general. Thus, the monomeric strategy
is no longer the most appropriate for developing clinically
useful drugs and we hypothesize that the approach should be
focused on heteromeric GPCRs. “A particular advantage of
receptor heteromers as targets for drug development is that
they can be involved in the pathophysiology of the disorder
being targeted. Thus, the receptor heteromer would be more
likely to be disease-specific than would the corresponding
monomeric/homomeric receptors” (Cortés et al., 2016). Newer
reports show that heteromer-selective drugs can exist in the
form of small-molecules, bivalent or multifunctional ligands, or
antibodies, displaying higher affinity and efficacy for a receptor
that forms a certain heteromer than for this receptor in another
heteromer or in the monomeric form (Orru et al., 2011; Gomes
et al., 2013c,b, 2016a; Cortés et al., 2016; Pulido et al., 2018;
Qian et al., 2018a,b).
In addition to heteromerization, drug discovery efforts
for cannabinoid receptors also involve the use of allosteric
cannabinoid ligands. One of the main problems of the use
of orthosteric ligands is their lack of selectivity among the
different members of a GPCR subfamily, because the orthosteric
binding sites are highly conserved (Conn et al., 2009). However,
the alosteric binding sites are less conserved and show greater
selectivity across different receptor subtypes (Conn et al., 2009).
The development of allosteric modulators of GPCRs in general,
and of CBRs in particular, have emerged as new approaches for
developing therapeutic drugs that may be useful for the treatment
of CNS disorders, without the inherent side effects of orthosteric
ligands (Foster and Conn, 2017; Nguyen et al., 2017; Scott and
Kendall, 2017). The development of biased allosteric modulators
of CB1R has also been showed as a promising way to selectively
modulate a therapeutically desirable CB1R signaling pathway
(Khajehali et al., 2015). Furthermore, there is the possibility
that the dimerization of GPCRs, and CBRs, could lead to the
appearance of an allosteric binding site, specific for the dimer
and non-existent in the individual protomers. This new allosteric
site has been reported for homocysteine in the A2AR-D2R
heterodimer (Agnati et al., 2006; Cervetto et al., 2018).
GXCR4-CB2R Heteromers in Cancer
It has been reported that CB2R can form heteromers with the
G protein-coupled chemokine receptor CXCR4 in human breast
and prostate cancer cells (Coke et al., 2016; Scarlett et al., 2018).
CXCR4 is implicated in various mechanism that enhance the
cell’s ability to proliferate and migrate, thus its activation has
been linked to local and distant metastatic invasion. Upon the
in vitro application of both CXCR4 and CB2R agonists however,
a reduction of the cell’s CXCR4-induced ERK1/2 dependent
migration has been documented, most likely due to the presence
of functional CXCR4-CB2R heteromers (Coke et al., 2016). This
heteromerization might enable cannabinoids to indirectly reduce
the invasive properties of cancer cells by inhibiting the effects
of CXCR4 agonists. The presence of CXCR4 and CB2R agonists
has also been associated with the inhibition of the Gα13/RhoA
signaling pathway in prostate cancer cells. The levels of RhoA and
Gα13 proteins decreased upon this dual stimulation, and led to an
abolishment of the cytoskeletal changes necessary for directional
cell migration (Scarlett et al., 2018). The invasive potential of the
cells was further decreased by an observed reduction of integrin
α5 expression in vitro, which is crucial for the cell’s ability to
adhere to the extracellular matrix. Over all, all these data identify
a novel pharmacologic target for the modulation of tumor cell
migration and invasion in the context of metastatic disease.
GPR55-CB2R Heteromers in Cancer
It has also been reported that CB2R and GPR55 are overexpressed
in many of cancer types (Henstridge et al., 2011; Velasco et al.,
2012), where they are crucial for the regulation of the cell fate
(Henstridge et al., 2011; Andradas et al., 2011; Piñeiro et al., 2011;
Velasco et al., 2012; Pérez-Gómez et al., 2013). As cannabinoids
modulate the activity of GPR55, its anti-cancer effects have been
analyzed as well.
CB2R/GPR55 transfected cells and breast cancer cells form
GPR55-CB2R heteromers with unique pharmacological and
signaling properties (Moreno et al., 2014). The expression of
the GPR55-CB2R heteromers influences cannabinoid signaling
in a way that their direct targeting using appropriate amounts
of THC might lead to a reduction of tumor growth, both in
vitro and in vivo. This is a promising new approach for the
development of drugs that target these heteromers in future
cancer-related studies. These results also help to explain the
potential molecular mechanisms behind the documented but still
poorly comprehended biphasic effects of cannabinoids, present
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in older reports concerning food intake, motor behavior, anxiety,
and others (Sulcova et al., 1998; Sañudo-Peña et al., 2000; Moreira
and Wotjak, 2010).
It might even be speculated that GPR55-CB2R heteromers
could exist and be crucial at other cancer-related sites, such as
bones or hematopoietic cells, where their overexpression has been
detected (Whyte et al., 2009; Balenga et al., 2011).
HER2-CB2R Heteromers in Cancer
In breast cancer, the overexpression of the tyrosine kinase
receptor (TKR) human V-Erb-B2 Avian Erythroblastic Leukemia
Viral Oncogene Homolog 2 (HER2) is a particular hallmark of
one type of this disease (Perou et al., 2000; Sorlie et al., 2001;
Sotiriou et al., 2003; Curtis et al., 2012). The activation of
TKRs engages crucial signaling pathways implicated in cellular
proliferation, development, differentiation, angiogenesis, and
other processes (Higgins and Baselga, 2011). Approximately
20–30% of primary breast cancer cells exhibit HER2 gene
amplification and protein overexpression which is a poor
prognostic biomarker and leads to an inadequate response to
chemotherapy (Moasser, 2007). At the same time, CB2R is
overexpressed in breast cancer, and it is present in especially high
levels in aggressive (high-grade) tumors (Caffarel et al., 2006;
Qamri et al., 2009; Caffarel et al., 2010).
There are very few examples of physical interaction between
RTKs and GPCRs, although several RTK-RTK heteromers
and GPCR-GPCR heteromers have been previously described.
Transactivation of RTKs by GPCRs and vice versa has been
observed, and in most cases physical interactions suggested,
but no solid evidence of the existence of heteromers has been
demonstrated (Pyne and Pyne, 2011).
The best characterized RTK-GPCR heteromer is produced
by HER2 and β2-adrenergic receptors in the heart and it is
essential for the cardiac homeostasis (Negro et al., 2006);
by fibroblast growth factor receptor and adenosine A2A
receptors (Flajolet et al., 2008) or serotonin 5-HT1A receptors
(Borroto-Escuela et al., 2012), which take part in synaptic
plasticity; and by EGFR and GPR54, which seem to induce breast
cancer cell invasiveness (Zajac et al., 2011).
The deregulation of the ECS in many cancers has
been extensively documented (Pacher et al., 2006;
Alpini and Demorrow, 2009; Pisanti and Bifulco, 2009; Caffarel
et al., 2012). Although there is a strong rationale for using
CB2R as an anti-cancer drug target (Guindon and Hohmann,
2011; Caffarel et al., 2012; Velasco et al., 2012), details on its
impact in tumor development and progression is still lacking.
The pro-oncogenic effect of CB2R in HER2+ breast cancer
was discovered when HER2-CB2R heteromers were detected in
these cells, and having observed a simultaneous appearance of
higher CB2 protein expression and poorer overall relapse-free
and metastasis-free survival of patients (Pérez-Gómez et al.,
2015). When there are no exogenous cannabinoids, CB2R
regulates HER2 signaling (Pérez-Gómez et al., 2015), which
was an unprecedented finding of CB2R-based control of HER2.
Thus, strategies based on the simultaneous targeting of these
two receptors (or their shared downstream effectors) may
prove effective (Pérez-Gómez et al., 2015). It would potentially
also mean that the combination of anti-HER2 drugs and
cannabinoids acting on CB2R may induce synergistic anti-
cancer effects. Recently, Blasco-Benito et al. (2019) proposed a
mechanism controlling the oncogenic activity of HER2 in breast
cancer through the HER2-CB2R heteromer. Inactivation and
degradation of HER2 and promotion of antitumor responses
is produced by the disruption of HER2-CB2R heteromer by
THC, which binds selectively to CB2R, or by using a synthetic
peptide with the amino acid sequence of specific transmembrane
5 domain (TM5) of the CB2R. All these findings reveal a
new mechanism of regulation of HER2 activity, and support
the existence HER2-CB2R heteromers as novel therapeutic
targets for HER2+ breast cancer (Pérez-Gómez et al., 2015;
Blasco-Benito et al., 2019).
The protein complexes CXCR4-CB2R, GPR55-CB2R and
HER2-CB2R possess particular pharmacological and signaling
properties, and their modulation might affect the antitumoral
activity of the ECS. So, the cannabinoid receptor heteromers
have a promising potential value as new targets for anti-cancer
therapies and as prognostic biomarkers (Figure 2).
Cannabinoid Ligands in Cancer
The use of endocannabinoids as anti-cancer therapeutics has
been extensively studied, and it can be concluded that they
generally exert protective and beneficiary effects, inhibiting
tumor growth and progression and restoring homeostasis.
However, endocannabinoids are very important regulatory
molecules involved in the metabolism of lipids and general
signaling non-related to cancer, and there are reports
that their levels can be elevated in some cancer subtypes
(Zhang et al., 2016). So they also might also contribute to the
pathogenesis and disease progression. Their interaction with
standard chemo- and targeted therapies needs to be taken into
account when exploring possible concurrent treatments, as
they might interfere with the cytotoxic mechanisms in question
(Miyato et al., 2009).
Since their discovery in the 1980s and 1990s, a lot of
data has been published using various experimental models
of cancer (from cell lines to genetically engineered mice)
showing that various cannabinoids can have anti-tumor
effects (Velasco et al., 2012). Endo- and exocannabinoids, as
well as many synthetic cannabinoid receptor agonists have
demonstrated this activity. Synthetic cannabinoids can have a
comparable affinity for CBRs (WIN 55,212-2, HU-210), or higher
affinity for one of them (methanandamide for CB1R, JWH-133
for CB2R). These findings add to the data load documenting
that pharmacologic stimulation of CBRs is generally anti-
tumorigenic. The induction of cancer cell death by apoptosis and
the inhibition of proliferation is usually the mode of action of
cannabinoids, in almost every tested cancer cell type (Velasco
et al., 2012). Furthermore, it has been shown that cannabinoids
reduce tumor angiogenesis as well as invasion/metastasis in vivo.
However, there are also studies that document tumor-promoting
effects of cannabinoids in vitro (Hart et al., 2004; Cudaback et al.,
2010), and those that suggest that they diminish the immune
system’s ability to act as a tumor-suppressor (Zhu et al., 2000;
McKallip et al., 2005).
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FIGURE 2 | A schematic representation of CB2R-CXCR4, CB2R-GPR55 and
CB2R-HER2 heteromers and their role as new targets in cancer. In Panel (A),
the activation of CB2R-CXCR4 heteromers inhibits prostate cancer cell
migration and adhesion. The binding of CXCL12 to its receptor, CXCR4,
induces CXCR4-mediated cell migration and adhesion. The application of
both CXCR4 and CB2R agonists inhibits the effect of CXCR4 agonist, due to
the presence of functional CB2R-CXCR4 heteromers. In Panel (B), the
hypothetical effect of THC on the CB2R-GPR55 heteromer. At low
concentrations, THC acts as a CB2R agonist promoting signaling. At higher
concentrations, THC targets GPR55, acting as an antagonist, and by
cross-antagonism, inhibits CB2R signaling. In Panel (C), the proposed
mechanism of control of the CB2R-HER2 heteromer in breast cancer is
shown. The HER2-CB2R heteromer is disrupted by THC or by using a
synthetic peptide with the amino acid sequence of specific transmembrane 5
domain (TM5) of the CB2R, triggering the inactivation of HER2 and producing
antitumor responses.
Cannabinoid Enzymes and Transporters
in Cancer
Targeting ECS enzymes and transporters has also been explored
as a therapeutic option with limited success, as any change
in endocannabinoid biosynthesis, degradation and transport
can have unpredictable effects in the organism. Changes in
the endocannabinoid metabolic pathways by interfering with
enzyme/transporter activity and levels can lead to an increased
availability of endocannabinoids and general protective effects,
especially in situations where these enzymes are deregulated as
a consequence of tumorigenesis, as is the case with MAGL in
colorectal cancer (Pagano et al., 2017). Many inhibitors of FAAH,
MAGL and transporters are being tested in various experimental
and clinical settings, alone and in combination (Ogawa
and Kunugi, 2015; Panlilio et al., 2016; Chicca et al., 2017;
Granchi et al., 2017), and many more are currently under
development. However, a range of non-psychotropic CNS and
systemic adverse effects needs to be thoroughly evaluated as
learning and memory impairment can occur upon treatment
(Panlilio et al., 2016).
CANNABINOID-INDUCED
ANTICANCER MECHANISMS
Cancer Cell Death
Antiproliferative action of many plant-derived, endogenous
and synthetic cannabinoids has been documented in
various in vitro cancer models (Bifulco and Di Marzo, 2002;
Guzmán, 2003). Also, in vivo experiments have confirmed
that treatment of nude mice with cannabinoids leads to
the formation of various tumor xenografts: lung carcinoma
(Munson et al., 1975), thyroid epithelioma (Bifulco et al., 2001),
lymphoma (McKallip et al., 2002), skin carcinoma (Casanova
et al., 2003) and glioma (Galve-Roperh et al., 2000). Glioma
cells have been used as the most common model system for
studying cannabinoid-induced anticancer mechanisms. Initial
studies showed that cannabinoids can induce apoptosis of
glioma cells via CB1R and CB2R dependent de novo synthesis of
the sphingolipid ceramide which has pro-apoptotic properties
(Galve-Roperh et al., 2000; Sanchez et al., 2001; Gomez del
Pulgar et al., 2002; Blázquez et al., 2004).
The level of cancer cell death resulting from the activation
of CBRs depends on the type of agonist that evoked the
response, and rarely on its mere affinity for a given CBR.
For example, the synthetic agonist WIN-55,212-2 has a higher
affinity for CBRs than THC, but lower concentrations of THC
are needed for the comparable cancer cell death-inducing
response (Pertwee et al., 2010). Beside the type of agonist, in
some cases the type of receptor that is activated determines the
resulting outcome. In glioma cells, the same level of inhibition
of cannabinoid-induced cell death is achieved by antagonizing
CB1R or CB2R, but in pancreatic, breast of hepatic cells
only CB2R antagonists are effective (Galve-Roperh et al., 2000;
Carracedo et al., 2006a; Caffarel et al., 2006; Lorente et al., 2011;
Vara et al., 2011). The mechanisms which regulate these
anti-cancer actions depending on agonist and receptor types
are still unknown.
Autophagy has proven as one of the crucial effects of
CBR agonists by which they promote cancer cell death.
There are reports showing that activation of CBRs in vitro
can lead to autophagy, and inhibition of autophagy via
genetic or pharmacological mechanisms in vivo counteracts
the anti-cancer effects of CBR agonists (Salazar et al., 2009;
Vara et al., 2011). In various cancer types, the cannabinoid-
induced autophagy is probably dependent on the p8 molecule,
as its signaling is often upregulated upon cannabinoid
treatment (Carracedo et al., 2006a,b; Salazar et al., 2009;
Vara et al., 2011). Various other regulatory pathways are
involved alongside with the p8-mediated autophagy, like an
ER stress-dependent upregulation of AMPK coupled with
TRIB3-induced downregulation of the AKT–mTORC1 pathway
in hepatocellular carcinoma (Vara et al., 2011). In melanoma
and breast cancer, activation of CBRs depends also on the
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downregulation of the AKT pathway (Blázquez et al., 2006;
Caffarel et al., 2006), and in gliomas on the activation of TRPV2
receptors (Nabissi et al., 2012; Velasco et al., 2015). When
hormone-dependent cancers are taken into account, cannabinoid
agonists might also act through cooperation with growth factor-
dependent pathways (Guzmán, 2003; Sarfaraz et al., 2008).
Thus, the anti-cancer effects of cannabinoids are mediated
by various mechanisms depending on the type of cancer cell
in question, leading to an autophagy-mediated cell death
(Guindon and Hohmann, 2011).
Regulation of Cancer Angiogenesis and
Local and Distant Invasion
It has been reported that the vascular endothelial growth
factor (VEGF)-induced cancer cell angiogenesis can be down-
regulated by the activation of CBRs in skin carcinomas
(Casanova et al., 2003), gliomas (Blázquez et al., 2003, 2004)
and thyroid carcinomas (Portella et al., 2003). Additionally,
CB1R and/or CB2R agonists lead to an inhibition of adhesion
and local and distant invasion in induced and spontaneous
metastatic in vitro and in vivo models of glioma, breast, lung,
and cervical cancer (Grimaldi et al., 2006; Blázquez et al., 2008;
Preet et al., 2008; Ramer and Hinz, 2008; Qamri et al., 2009).
Notably, it has been reported that when ceramide biosynthesis is
inhibited in vitro or in vivo, the anti-cancer and anti-angiogenic
effects of CBR activation are abolished (Blázquez et al., 2004).
It is also important to note that CBD acting through non-
receptor based mechanisms can generate a significant anti-cancer
effect leading to a decrease of the invasive and metastatic
potential in various animal cancer models (Velasco et al., 2015).
Anticancer Immunity Regulation
There are reports that ligand binding to CB2Rs can create a
pro-tumorigenic surrounding by interfering with the immune
system-mediated tumor surveillance mechanisms (Zhu et al.,
2000; McKallip et al., 2005). On the other hand, cannabinoids
have also been shown to enhance the tumor surveillance in
melanoma xenografts in immunocompetent mice compared to
immunodeficient mice, when using a synthetic cannabinoid WIN
55212-2 or JWH-133 (Blázquez et al., 2006; Velasco et al., 2015).
Thus, the role of ECS is again dual depending on tumor type
and the overall state of the immune system. Additionally, the
formation of specific CBR homo- and heterooligomers upon
stimulation with cannabinoids, and the subsequent change
in their subcellular localization and coupling to G proteins
contributes to the complexity of this issue (Velasco et al., 2015).
ETHICAL AND LEGAL ASPECTS OF
USING ECS COMPONENTS IN
ANTI-CANCER THERAPY
As drug repurposing is significantly faster and more economical
than de novo introduction of a new drug into the clinic, there
is hope that the existing pharmacokinetic and safety data on
various ECS components might contribute to their successful
translation into oncological healthcare. However, many ethical
and legal issues need to be addressed carefully especially before
the use exogenous cannabinoids as anti-cancer drugs can become
a reality. And while it appears that there are no obvious
ethical and legal issues in targeting ECS enzymes/transporters
or using endocannabinoids as anti-cancer drugs compared to
the issues that exists with exogenous products, the matter of
tumor-specificity and adverse effects of endogenous ECS-based
approaches needs to be the main research objective.
Ethical Dilemmas on Using Exogenous
Cannabinoids in Medicine
The debate over legalizing medical marijuana started heating
up in the United States in the 1970, when the Controlled
Substances Act was passed by the Congress. According to this
Act, marijuana was listed as a schedule I drug which “has a
high potential for abuse, no currently accepted medical use and
lacks safety for use under medical supervision.” Being classified
under the hallucinogenic substances category, the sale, purchase
or consumption of marijuana became illegal.
The debate on whether marijuana can cause addiction
and can seriously affect physiological state is still ongoing.
Upon smoking cannabis, its active substances rapidly enter
the blood stream and are quickly carried to the brain.
With regular, heavy use, severe symptoms might arise such
as depression, anxiety, irritability, bronchitis, conjunctivitis
and endocrine disorders (Volkow et al., 2014). Although
animal studies show that it can affect the immune system,
there are no studies in humans that definitively correlate
the immunosuppressive effects with either increased incidence
of infections or immune disorders (Cabral and Staab, 2005).
Short term cognitive effects include impairment of short
term memory, sensory perception, attention span, problem
solving, impaired motor coordination and psychomotor control,
distorted judgment, and paranoia and psychosis in cases when
higher doses are used (Volkow et al., 2014). It was shown that
concurrent smoking of tobacco and marijuana synergistically
increases the predisposition to respiratory problems and even
chronic obstructive pulmonary disease (COPD). Smoking only
marijuana cannot be directly associated with an increased risk of
these problematic respiratory states (Tan et al., 2009).
The American Cancer Society (ACS) reported that marijuana’s
harmful substances are introduced into the body in a similar
manner as tobacco consumption delivers cancer-causing
substances. On the other hand, the ACS states that marijuana
can alleviate suffering from pain when traditional medicine
methods are exhausted. The ACS does not advocate the
legalization of marijuana or its use, but they do support more
research that would lead to exploitation of its benefits. Mixed
reports on the causal relationship of chronic cannabis use
and increased risk of cancer are showed in epidemiological
literature (Hashibe et al., 2005). Hashibe et al. (2005) found that
smoking cannabis was not associated with an increased risk
of smoking-related cancers (e.g., lung, head, and neck), but
might be associated with an increased risk of prostate cancer,
cervical cancer, and glioma. Conversely, Reece reported that
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smoking cannabis is associated with an increased risk of lung
cancer (Reece, 2009). Interestingly, Maertens et al. (2013)
found that aside from the cannabinoids and nicotine, cannabis
and tobacco smoke condensates contained mixtures that were
similar. They also found that cannabis smoke condensate
and tobacco smoke condensate influence the same molecular
processes but have subtle pathway differences that potentially
account for differential toxicities and the mixed results with
respect to lung cancer. Even highly controversial, these potential
hazards for the individuals seem to be good reasons to justify
monitoring and to limit the access to the cannabis use. On the
other hand, fear of legal consequences, ethical issues, social and
legal barriers, stigma associated with abuse and lack of funding
may interfere with the important research on the therapeutic
potential of these controversial substances. These impediments
could obstruct the research that might not just have the potential
to alleviate chronic suffering and exploring harm reduction
(Abrams, 1998) but might also have the potential to treat serious
illnesses such as cancer.
While deciding on the policies, all harms and benefits of
using cannabinoids should be taken into consideration. Also,
the harms and benefits that are likely to result from the
regulations that limit the access, use and the research on
specific drugs must be taken into account. It is required that
clinical trials minimize the risks for research subjects and to
protect them from unreasonable risk. Reports documenting that
cannabinoids reduce pain, nausea and spasms exist (Tramèr
et al., 2001; Kalso, 2001), but it has also been argued that
these medicinal benefits are overshadowed by the risks and
the harmful side effects. There is also the argument of the
lack of real need for its use in pain management since many
other safer drugs are available (Kalso, 2001). To put more
weight on the side of caution, legal and social risks must not
be disregarded. Based on its unpopular and stigmatized use
mostly in the Western countries, it seems that decisive clarity
on whether benefits outweigh the risks of cannabinoid use
for medical purposes will not be reached in the near future.
When professionals’ opinions are taken into consideration, it
seems that the majority of medical doctors are in favor of
medical marijuana use.
In this ongoing debate, the main arguments for allowing
cannabis use come from the ideas of autonomy and freedom.
Although the notion of autonomy has been used in many
different relations, in biomedical ethics the idea of autonomy
actually means self-government. The point of view that the
value of patients’ autonomy is more important than the value
of protecting the patients’ well-being highlights the bioethical
issues that arise in the context of clinical research (Varelius, 2006).
The definition of autonomy most often used in medical ethics is
derived from the philosophy of Immanuel Kant who proposed
that autonomy means personal self-determination. According to
his doctrine, people can act “truly free” only if they act to their
desires, attitudes or emotions. One could argue that cannabis
use should not be forbidden to anyone, especially since there
is a valid medical basis for its use. However, one could also
argue that the use of psychoactive substances leads to addiction
and clouds a person’s judgment which seriously confronts the
Kantian model since addiction is prone to hinder self-determined
decision making.
The formal bioethical principle of justice requires treating
similar cases alike and different case differently. This concept
also emphasizes fairness and equality among individuals. Since
marijuana is listed as harmful and addictive and is banned as a
class I drug, it can be stated that other harmful drugs as nicotine
in the form of cigarettes and alcohol should be regarded alike
and should not be allowed for use. The main question involving
social justice can be formulated in the following manner: is it just
to allow the research of substances that may alleviate conditions
in one patient and prohibit or limit research on substances that
might be the only ones that can help another patient? If the
answer is yes, additional questions arise. When should such
research be limited, why and by whom? Who is to decide about
the fairness of the research? (Andreae et al., 2016). Respecting
the autonomy and following the notion of social justice it does
appear that marijuana should be legalized for medicinal use from
the ethical point of view. Legalization of marijuana would be an
example of utilitarianism if the positive outcome of such an action
would outweigh the negative consequences. In case we consider
drug use not only for symptoms alleviation but for the treatment
of the disease itself, it seems that this risk/benefit calculation may
be favorable in terms of greater benefits. While assessing physical
risks we must not forget the psychological, social, legal risks and
risks regarding privacy issues. Also, many risks vocalized through
the media tend to be exaggerated and may distort our judgment
of the real risks.
Legalization Issues
In June 2018, Canada made history by passing the Bill C-45 which
is officially known as the Cannabis Act. By doing this, Canada has
become the first industrialized nation in the world to have passed
legislation allowing adults to purchase marijuana for recreational
use. The only country in the world that has similar legislation so
far is Uruguay. Per the Canadian law, adults over the age of 18
are allowed to purchase marijuana, as well as possess up to 30 g
of dried cannabis for personal consumption (Canada Gov, 2018;
CTV, 2018). Sale to minors is strictly prohibited.
Aside from Canada, USA’s Vermont became the first US
state to allow use of recreational cannabis entirely through
the legislative process in the beginning of 2018. Meanwhile,
Oklahoma passed legislation that legalized medical marijuana.
Even though their approaches might be slightly different, 30
states in the United States allow marijuana for medical purpose
(“Marijuana Is Legal for Medical Purposes in 32 States – Vox”
2018). This changing perception toward cannabis has been
happening almost everywhere in the world and a growing
number of countries have legalized medical marijuana to some
extent. The use of marijuana in the medical setting has been
fully legalized in Czechia. The Netherlands has also legalized its
use and restricted it to “coffee shops,” while outside of coffee
shops, it is considered illegal (although decriminalized) to possess
a maximum of 5 g or 5 plants. Poland, Romania, Norway,
Germany, Italy, Greece have all legalized access for medical
use. There are some European countries where cannabis is not
legalized for smoking such as France, Spain and Slovenia but the
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use of cannabis-derived drugs is permitted. In Israel, Romania,
Macedonia and Puerto Rico, marijuana use is illegal, but has been
made available in cases of severe or terminal illnesses. Following
the examples of Uruguay, nine states in the United States
and most recently Canada, there have been many initiatives to
propose legalizing cannabis in the more restrictive counties. For
example, Spain has reignited the debate over legalizing marijuana.
In Australia medical marijuana is legal at the federal level but the
implementation is not the same in all states. In Victoria and New
South Wales a cannabis card is necessary, and in the Australian
Capital Territory and South Australia personal cultivation of up
to two plants is allowed.
According to the UN survey (CNN, 2018) over 10,000 tons
of cannabis is produced in the African continent each
year and Africa appears to be the next large market for
cannabis legalization. In May 2018, Zimbabwe legalized growing
marijuana for medicinal and research purposes. Similarly,
Lesotho began approving medical marijuana culturing licenses
in 2017. The UN Office on Drugs and Crime reported that
Morocco is the second-largest producer of cannabis in the world.
Because of the huge potential that this industry could have
on Morocco’s economy, in 2014 the bill to legalize marijuana
production for medical and industrial use was proposed in the
Moroccan parliament. The bill failed at the time due to political
and religious reasons and it seems that it will be difficult to
overcome them any time soon.
CLINICAL TRIALS
Clinical trials have shown important findings investigating
various components of the ECS (Table 2). FAAH is a membrane
enzyme that degrades anandamide and is therefore a very
attractive pharmacological target in many diseases. Many efforts
have been employed to design and test new FAAH inhibitors
or modulators of its activity (Lodola et al., 2015). However, the
very unfavorable outcome of the French phase I study using
the BIA 10-2474 FAAH inhibitor on healthy human volunteers
is a dramatic example of how unpredictable the translation of
ECS-based drugs into the clinic can be (Kaur et al., 2016).
Currently, there are no approved FAAH inhibitors in clinical
use, although the US FDA (in collaboration with the European
Medicines Agency and the French national medicines agency)
released a statement after the failure of this trial that other
classes of FAAH inhibitors do not pose similar safety risks
(FDA, 2016).
Because of its key role in the degradation of the 2-AG,
targeting MAGL represents an interesting therapeutic target. In
addition, MAGL is over-expressed in various cancers (breast,
ovarian, melanoma) thus its inhibition can lead to a decrease
of migration of cells and their invasiveness (Granchi et al.,
2017). Also, MAGL controls the release of fatty acids from
lipid-rich cancer cell compartments, which can lead to an
activation of lipid signaling pathways implicated in migration,
invasion, survival, and tumor growth. Thus, MAGL inhibitors
have proven as promising candidates for anti-cancer therapy.
Because of its specific properties, many compounds with a
MAGL inhibition activity were investigated by academia and
pharmaceutical companies. MAGL inhibitors have been patented
for a large number of therapeutic uses, mainly covering the area of
pain and inflammation, metabolic disorders (such as obesity and
diabetes), neurodegenerative pathologies (such as Alzheimer’s
disease), as well as the treatment of cancer, anxiety, and epilepsy
(Granchi et al., 2017).
Following the example of Ben Amar who reviewed the existing
clinical trials using cannabis and exogenous cannabinoids
from 1975 to June 2005 (Ben Amar, 2006), two review
papers were issued in 2010 and in 2014 reporting more
recent clinical trial data. Both of these reviews were based
on systematic research of PubMed for published randomized
(double) blinded, placebo-controlled clinical trials, using the
following keywords: cannabis, marijuana, marihuana, hashish,
cannabinoid(s), tetrahydrocannabinol, THC, CBD, dronabinol,
Marinol, nabilone, Cannador, nabiximols and Sativex.
In the review that covered period between
2006 and 2010, 37 such studies were identified
(Hazekamp and Grotenhermen, 2010a), and 8 main indications
of cannabinoid use were: neuropathic or chronic pain,
experimental pain, multiple sclerosis and spasticity, HIV/AIDS,
glaucoma, intestinal dysfunction, nausea/vomiting/appetite
and schizophrenia. Based on the data presented in this study,
cannabinoids showed most promise for the treatment of multiple
sclerosis, but also as analgesics in chronic neuropathic pain and
as appetite stimulants in cancer and AIDS. A wide range of
cannabis-based drugs exhibited analgesic effects on various types
of chronic and neuropathic pain with the majority of the adverse
effects being mild or moderate, while they did not have such a
prominent effect on acute types of pain.
One of the first studies performed to evaluate cannabinoid
antitumoral action was performed by Guzmán and collaborators,
who showed that cannabinoids can inhibit tumor growth
(Guzmán, 2003). Due to the ethical and legal issues discussed
previously, the first studies were conducted in terminal patients
with recurrent tumors (Guzmán et al., 2006). These first trials
shed the light not just on the palliative effects, but also on
the possible antitumoral effects of cannabinoids, alone or in
combination with other drugs as well.
In the review that covered the period between 2010 and
2014, 32 controlled studies were reported that further
investigated the therapeutic potential of cannabinoids
(Hazekamp and Grotenhermen, 2010b). Eleven main indications
for which cannabinoids showed greatest treatment potential
included: chronic pain, multiple sclerosis, irritable bowel
syndrome, Crohn’s disease, appetite and chemosensory
perception, chemotherapy-induced nausea and vomiting,
pulmonary diseases, cannabis dependence, psychosis and
Parkinson’s disease. Compared to the previous report period, the
effect of oral cannabis on patients suffering from chronic pain
was much more investigated, as there was an increase in the
number of patients participating in pain-related clinical trials.
Because of the various limitations of cannabinoid use in a clinical
setting for most of the investigated conditions, chronic pain
currently remains the major field of research interests as it is
linked to less controversy while providing an acceptable benefit.
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There are many review papers and meta-analyses discussing
the safety, toxicology and therapeutic effects of exogenous
cannabinoids. Out of the 70 known cannabinoids derived
from the plant Cannabis sp., variety of synthetic cannabinoids
and cannabinoid extracts, THC and CBD are the most
commonly researched cannabinoids in the literature. Different
methods of administration, inconsistent dosing measures, and
highly variable cannabinoid content of cannabis plants only
add to the already complex interactions of exogenous and
endogenous cannabionids. Factors such as light, temperature,
humidity, and soil type during cultivation, genetic factors,
the method of administration (e.g., oral, smoked, vaporized)
and form of cannabinoid consumed (e.g., stems and buds,
hashish, hash oil, extract, synthetic) can impact the response
to use. Since future clinical trials focusing on anticancer
effects of cannabinoids will most likely not be conducted
as monotherapy, research studies concerning probable
interactions between cannabinoids and cytostatic drugs have
shown promising effects. For example, THC and CBD
enhance the cytotoxic impact of several chemotherapeutics
such as cytarabine, doxorubicin, mitoxantrone, carmustine,
temozolomide, bortezomib, carfilzomib and cisplatin (Ramer
and Hinz, 2017). THC and CBD have been also shown to enhance
the cytostatic effect of vinblastine in resistant leukemia cells and
of mitoxantrone in embryonic fibroblasts (Holland et al., 2006,
2007). An enhancement of the cytostatic properties of cytarabine,
doxorubicin and vincristine has, likewise, been substantiated for
THC in leukemia cells (Liu et al., 2008). Synergistic actions were
further reported for the effect of a CBD/THC combination added
to multiple myeloma cells in the presence of carfilzomib. The
susceptibility of glioblastoma cells for the cytotoxic action of
cisplatin was found to be enhanced by CBD (Deng et al., 2017).
In 2017, phase II, randomized, placebo-controlled clinical trial
with recurrent glioblastoma multiforme patients was announced
and showed the potential efficacy of cannabinoids as add-on anti-
cancer drugs. 12 patients were randomized to a combination
of THC and CBD in addition to dose-intensive temozolomide,
whereas 9 patients were randomized to placebo plus standard
of care. This study showed a significantly higher one year
survival rate in the cannabinoid group (83% vs. 53%), and
the median survival for the cannabinoid group was greater
than 550 days comparing to 369 days in the placebo group
(GW Pharmaceuticals, 2017 press release; ClinicalTrials.gov
Identifiers: NCT01812616, NCT01812603).
FUTURE DIRECTIONS
Although the ECS has been studied in detail by many research
groups for decades, its clinical value as an anti-cancer target
is still under debate. More intensive basic research is needed
for a more precise characterization of the biochemical ECS
mechanisms that are crucial in the cancer-setting, especially
when cannabinoid-based/standard drug combinations are taken
into account. Rigorous testing before any such drug should
advance to phase-I clinical trials needs to be a matter of global
consensus. Proper selection of target patient groups needs to be
intensified to comply with all Good Clinical Practice regulations,
as well as bioethical principles and legal boundaries, in order
to achieve the right drug response in the right patient at
the right moment.
CONCLUSION
There is an overwhelming burden of evidence that the ECS
and all its components is an attractive anti-cancer target, but
different strategies are yet to be rigorously clinically tested in
order to exploit its full potential, such as explore the value of
cannabinoid receptor heteromers as potential new targets for
anti-cancer therapies and as prognostic biomarkers. Taking into
account all the ethical issues involved in the use of ECS exogenous
ligands in anti-cancer therapy and the number of ongoing clinical
trials, we are definitely still not there yet, but the route is firm and
sprinkled with hope for success.
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